Medial Flap Versus Coblation-Assisted Turbinoplasty For Turbinates Hypertrophy: A Prospective Randomized Controlled Trial.

Otolaryngol Head Neck SurgJul 3, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)Open access

Amani Daoud, Shiri Geva, Amiel Dror et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective randomized controlled trial compared medial-flap turbinoplasty (MFT) and coblation-assisted turbinoplasty (CAT) for treating inferior turbinate hypertrophy in patients with persistent nasal obstruction. The study found that MFT provided significantly greater long-term symptom relief at 12 months, with a NOSE score of 18.5 compared to 34.5 for CAT (P = .027).

Key findings

  • Both MFT and CAT showed significant symptom improvement at all time points (P < .0001).
  • MFT resulted in a NOSE score of 18.5 vs 34.5 for CAT at 12 months (P = .027).
  • MFT demonstrated greater turbinate size reduction (P < .001) and less postoperative crusting.

Why it matters

Understanding the long-term efficacy of different surgical techniques for inferior turbinate hypertrophy is crucial for optimizing patient outcomes. This study highlights the potential benefits of MFT in achieving sustained symptom relief and fewer complications.

Source

PubMed · PMID 42398225Free full text on PubMed Central

Published in Otolaryngol Head Neck Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.